Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Dec 1;168(6):2193–2206. doi: 10.1084/jem.168.6.2193

Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell- mediated immunity

PMCID: PMC2189164  PMID: 2974065

Abstract

This study shows that intravenous injection of 1 mg of anti-L3T4 mAb (GK1.5) into thymectomized mice bearing the syngeneic L5178Y lymphoma results, after a delay of 2-3 d, in complete regression of this tumor and in long-term host survival. A flow cytofluorometric examination of the spleen cells of mAb-treated mice revealed that antibody treatment resulted in the elimination of greater than 98% of L3T4+ T cells, but had no effect on the Lyt-2+ T cells subset. Tumor regression was immunologically mediated, because L5178Y lymphoma cells were shown to be L3T4-, and regression of the tumor failed to occur in mice that had been lethally irradiated before anti-L3T4 mAb was given. Tumor regression was mediated by tumor-sensitized Lyt2+ T cells, as evidenced by the finding that treatment of tumor-bearing mice with anti-Lyt-2 mAb alone, or in combination with anti-L3T4 mAb, resulted in enhancement of tumor growth and a significant decrease in host survival time. Moreover, the spleens of mice whose tumors were undergoing regression in response to anti-L3T4 mAb treatment contained Lyt-2+ T cells capable, on passive transfer, of causing regression of a tumor in recipient mice. These results can be interpreted as showing that removal of tumor-induced L3T4+ suppressor T cells results in the release of Lyt-2+ effector T cells from suppression, and consequently in the generation of enough Lyt-2+ T cell-mediated immunity to cause tumor regression. This can only be achieved, however, if immunity to the tumor is mediated exclusively by Lyt-2+ T cells, as is the case for the L5178Y lymphoma. In the case of the P815 mastocytoma, treatment with anti-L3T4 mAb was without a therapeutic effect, and this was in keeping with the finding that immunity to this tumor is mediated by L3T4+, as well by Lyt-2+ T cells.

Full Text

The Full Text of this article is available as a PDF (820.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awwad M., North R. J. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 1988 Sep;65(1):87–92. [PMC free article] [PubMed] [Google Scholar]
  2. Awwad M., North R. J. Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity. Cancer Immunol Immunother. 1988;26(1):55–60. doi: 10.1007/BF00199848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Butler L., Simmons B., Zimmerman J., Deriso P., Phadke K., Hom J. Regulation of cellular and humoral immune responses to collagen type I or collagen type II. Immunology. 1988 Apr;63(4):611–617. [PMC free article] [PubMed] [Google Scholar]
  4. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  5. Digiacomo A., North R. J. Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour. Immunology. 1987 Mar;60(3):367–373. [PMC free article] [PubMed] [Google Scholar]
  6. Dye E. S., North R. J. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation. 1984 Jun;37(6):600–605. doi: 10.1097/00007890-198406000-00015. [DOI] [PubMed] [Google Scholar]
  7. Dye E. S., North R. J., Mills C. D. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med. 1981 Sep 1;154(3):609–620. doi: 10.1084/jem.154.3.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res. 1983;39:71–120. doi: 10.1016/s0065-230x(08)61033-7. [DOI] [PubMed] [Google Scholar]
  9. Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985 May 1;161(5):1122–1134. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Johnson T. R., North R. J. Frequency analysis of augmented CTL production associated with Corynebacterium parvum-induced tumour regression. Immunology. 1987 Mar;60(3):361–366. [PMC free article] [PubMed] [Google Scholar]
  11. Liew F. Y., Hale C., Howard J. G. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells. J Immunol. 1982 Apr;128(4):1917–1922. [PubMed] [Google Scholar]
  12. Madsen J. C., Peugh W. N., Wood K. J., Morris P. J. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts. Transplantation. 1987 Dec;44(6):849–852. [PubMed] [Google Scholar]
  13. North R. J. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1–43. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
  14. North R. J., Dye E. S. Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology. 1985 Jan;54(1):47–56. [PMC free article] [PubMed] [Google Scholar]
  15. North R. J. Models of adoptive T-cell-mediated regression of established tumors. Contemp Top Immunobiol. 1984;13:243–257. doi: 10.1007/978-1-4757-1445-6_12. [DOI] [PubMed] [Google Scholar]
  16. Ozawa H., Iwaguchi T., Kataoka T. The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice. Cancer Immunol Immunother. 1986;23(1):73–77. doi: 10.1007/BF00205559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sadick M. D., Heinzel F. P., Shigekane V. M., Fisher W. L., Locksley R. M. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells. J Immunol. 1987 Aug 15;139(4):1303–1309. [PubMed] [Google Scholar]
  18. Shizuru J. A., Gregory A. K., Chao C. T., Fathman C. G. Islet allograft survival after a single course of treatment of recipient with antibody to L3T4. Science. 1987 Jul 17;237(4812):278–280. doi: 10.1126/science.2955518. [DOI] [PubMed] [Google Scholar]
  19. Shizuru J. A., Taylor-Edwards C., Banks B. A., Gregory A. K., Fathman C. G. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988 Apr 29;240(4852):659–662. doi: 10.1126/science.2966437. [DOI] [PubMed] [Google Scholar]
  20. Suzuki F., Brutkiewicz R. R., Pollard R. B. Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli. J Natl Cancer Inst. 1986 Aug;77(2):441–447. [PubMed] [Google Scholar]
  21. Titus R. G., Ceredig R., Cerottini J. C., Louis J. A. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J Immunol. 1985 Sep;135(3):2108–2114. [PubMed] [Google Scholar]
  22. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES